

Accepted Manuscript

Lower extremity deep venous thrombosis in a multiple sclerosis patient on Dimethyl Fumarate

Omid Mirmosayyeb , Emad Fayyazi , Vahid Shaygannejad ,
Nafiseh Esmaeil

PII: S2211-0348(18)30257-8
DOI: [10.1016/j.msard.2018.07.037](https://doi.org/10.1016/j.msard.2018.07.037)
Reference: MSARD 912



To appear in: *Multiple Sclerosis and Related Disorders*

Received date: 2 June 2018
Revised date: 14 July 2018
Accepted date: 20 July 2018

Please cite this article as: Omid Mirmosayyeb , Emad Fayyazi , Vahid Shaygannejad , Nafiseh Esmaeil , Lower extremity deep venous thrombosis in a multiple sclerosis patient on Dimethyl Fumarate, *Multiple Sclerosis and Related Disorders* (2018), doi: [10.1016/j.msard.2018.07.037](https://doi.org/10.1016/j.msard.2018.07.037)

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Lower extremity deep venous thrombosis in a multiple sclerosis patient on Dimethyl Fumarate

Omid Mirmosayyeb^{1,2}, Emad Fayyazi^{1,2}, Vahid Shaygannejad^{1,3}, Nafiseh Esmaeil⁴

¹ Isfahan neurosciences research center, Alzahra research institute, Isfahan University of medical sciences, Isfahan, Iran

² Student Research Committee, Isfahan University of medical sciences, Isfahan, Iran

³ Department of neurology, Isfahan University of medical sciences, Isfahan, Iran

⁴ Department of immunology, Isfahan University of medical sciences, Isfahan, Iran

Corresponding author:

Prof. Vahid Shaygannejad - Department of neurology, Isfahan University of medical sciences, Isfahan, Iran - Tel: +989133133550 - E-mail: v.shaygannejad@gmail.com

Word count: 556

Dear All,

Dimethyl Fumarate (DMF) (BG-12; Tecfidera) has immune-modulatory and neuro-protective effects which has been approved for treatment of some disorders such as multiple sclerosis (MS) (1) and psoriasis (2). It could be beneficial as a potential agent in the treatment of multiple sclerosis by reducing inflammation. The adverse effects of DMF, which have been reported in clinical trials, are mainly flushing, gastrointestinal events, proteinuria, and pruritus. In this report,

Download English Version:

<https://daneshyari.com/en/article/8647292>

Download Persian Version:

<https://daneshyari.com/article/8647292>

[Daneshyari.com](https://daneshyari.com)